Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin
- 1 May 1993
- journal article
- clinical trial
- Published by Springer Nature in Osteoporosis International
- Vol. 3 (S3) , 21-27
- https://doi.org/10.1007/bf01623004
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Bone density at various sites for prediction of hip fracturesThe Lancet, 1993
- Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in ratsJournal of Bone and Mineral Research, 1992
- Comparison of the therapeutic potencies of two bisphosphonatesBone, 1992
- The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboonsJournal of Bone and Mineral Research, 1992
- Intranasal Salmon CalcitoninDrugs & Aging, 1991
- Appendicular skeletal status and hip fracture in the elderly: 14-year prospective dataBone, 1991
- Effect of Intermittent Cyclical Etidronate Therapy on Bone Mass and Fracture Rate in Women with Postmenopausal OsteoporosisNew England Journal of Medicine, 1990
- NASAL CALCITONIN FOR TREATMENT OF ESTABLISHED OSTEOPOROSISClinical Endocrinology, 1989
- Age and bone mass as predictors of fracture in a prospective study.Journal of Clinical Investigation, 1988
- Involutional OsteoporosisNew England Journal of Medicine, 1986